Results 121 to 130 of about 21,592 (229)
Baseline and follow-up data for non–alendronate and alendronate patients.
Abbreviations: BMD, bone mineral density; BUN, blood urea nitrogen; C-Ca, serum corrected calcium; Cr, blood creatinine; CMV, cytomegalovirus; DM, diabetes mellitus; FN, femoral neck; H, hip; HBV, hepatitis B virus; HCV, hepatitis C virus; LS, lumbar ...
Ping-Chin Lai (297993) +3 more
core +1 more source
Efficacy and Safety of Generic Alendronate for Osteoporosis Treatment
Atthakorn Jarusriwanna,1,* Saran Malisorn,1,* Sirikarn Tananoo,1 Kwanchanok Areewong,2 Supachok Rasamimongkol,1 Artit Laoruengthana1 1Department of Orthopaedics, Faculty of Medicine, Naresuan University, Phitsanulok, Thailand; 2Department of ...
Areewong K +5 more
core
In-vitro release of alendronate sodium from different formulations.
In-vitro release of alendronate sodium from different formulations.
Waleed Yousof Rizg (5328671) +1 more
core +1 more source
Background Osteogenesis imperfecta (OI) is a genetic disorder of connective tissue caused by mutations associated with type I collagen, which results in defective extracellular matrix in temporomandibular joint (TMJ) cartilage and subchondral bone.
Po-Jung Chen +3 more
doaj +1 more source
The aim of the present study was to evaluate the effects of alendronate, calcitonin and raloxifene used in the treatment of postmenopausal osteoporosis on serum nitric oxide (NO) levels.
Kazım Şenel +5 more
core
Precise techniques for the measurement of maxillary bone mineral density (BMD) are useful for the early diagnosis of systemic diseases. The aim of this study was to compare in vivo the efficacy of dual-energy x-ray absorptiometry (DXA) and radiographic ...
Marília Pacífico Lucisano +6 more
doaj
Jun Iwamoto1, Atsushi Miyata2, Yoshihiro Sato3, Tsuyoshi Takeda1, Hideo Matsumoto11Institute for Integrated Sports Medicine, Keio University School of Medicine, Tokyo, Japan; 2Department of Internal Medicine, Yahata Clinic, Tokyo, Japan; 3Department of ...
Atsushi Miyata +3 more
core
The Effect of Alendronate Treatment on Bone Density and Bone Markers in Postmenopausal Osteoporosis
The objective of this blind, randomized controlled study was to evaluate effect of 12 months alendronate treatment on bone mineral density (BMD) and bone formation, resorption markers in postmenopausal osteoporotic women. Women with BMD values at least 2
S. Akı, N. Eskiyurt, R. G. Gulbaba
core
Effects of Alendronate and Alfacalcidol on Preventing Bone Loss in Chemotherapy-treated Soft-tissue Sarcoma. [PDF]
Nakanishi M +10 more
europepmc +1 more source
Prescribing Trends of Osteoporosis Medications, Adherence and Persistence with Denosumab versus Alendronate: A Real-World Retrospective Study in China. [PDF]
Chen J, Huang Y, Liu P, Fan L.
europepmc +1 more source

